Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AZ Joins Spin-Out Set, Forms GI Play Albireo

This article was originally published in Start Up

Executive Summary

AstraZeneca has completed its first ever biotech spin out, creating the Swedish biotech firm Albireo with backing led by Nomura Phase4 Ventures. The deal underscores pharma's disenchantment with certain aspects of GI drug development and may blaze a trail for other non-core areas of R&D at the drugmaker.

You may also be interested in...



NASH Companies Take The Stage At AASLD

NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.

Albireo Making Headway In Rare Pediatric Liver Diseases With IBAT Inhibition

Biotech hopes to launch a Phase III trial in the rare disorder PFIC before year’s end. It thinks its therapy could offer similar benefits to surgery in reducing pruritus and improving liver parameters.

AZ Spins Out Entasis To Tackle Resistant Infections

AstraZeneca has, after a long gestation, given birth to the antibiotic developer Entasis Therapeutics: in early July the biotech debuted with $40 million in funding from AZ alone, and a portfolio of the drugmaker’s early-stage antibiotic candidates. It emerges as the debate about incentivizing antibiotics R&D intensifies amid growing concerns about antibiotic-resistant bacteria.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091546

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel